SARM1 Inhibitors Market By Application (ALS, Peripheral Neuropathies, Traumatic Brain & Spinal Cord Injuries, MS, Chemotherapy-Induced Neuropathy, Others); By Molecule Type (Small Molecule Inhibitors, Biologics & Peptides, Gene & RNA-based Approaches); By Distribution Channel (Hospital Pharmacies, Specialty Clinics, Online & Specialty Pharmacies); By Geography, Segment Revenue Estimation, Forecast, 2024–2030

SARM1 Inhibitors Market Advances as Axon-Protection Pipelines Target Neuropathy and Neurodegeneration (Last Updated on: June-2026)

The Global SARM1 Inhibitors Market is projected to register strong growth at a CAGR of 28.5%, increasing from USD 120 million in 2024 to USD 540 million by 2030.

 

The SARM1 inhibitors market is an early-stage neuroprotection opportunity focused on preventing axon degeneration rather than managing neurological symptoms after damage has occurred. As of 2026, no SARM1 inhibitor has received FDA approval, but clinical and preclinical programs are advancing across chemotherapy-induced peripheral neuropathy, ALS, multiple sclerosis, diabetic neuropathy, traumatic nerve injury, and broader axonopathy-related disorders.

 

SARM1, or sterile alpha and TIR motif containing 1, is increasingly viewed as a central execution point in programmed axon degeneration. When activated by injury, toxic stress, or disease, SARM1 rapidly depletes NAD+, weakening axonal energy balance and triggering structural breakdown. SARM1 inhibitors are designed to block this NADase activity, preserve axonal integrity, and delay or prevent nerve-fiber loss.

 

The market is therefore not being built around symptomatic relief alone. Its value depends on whether axon preservation can be translated into measurable clinical outcomes such as lower neuropathy severity, preserved nerve function, slower disability progression, improved chemotherapy continuity, or biomarker-supported neuroprotection.

 

Market Scope and Development Logic

The SARM1 inhibitors market covers therapeutic candidates designed to suppress SARM1 activity and prevent NAD+ depletion in injured or stressed axons. The most active development area is oral small-molecule inhibition, including allosteric inhibitors, active-site inhibitors, and newer approaches intended to preserve axonal structure across peripheral and central nervous system disorders.

This is not yet a commercial prescription market. It is a translational neuroscience market where value is tied to clinical proof, biomarker validation, endpoint selection, and indication prioritization. The most important near-term signals are Phase I safety, proof-of-biology data, Fast Track activity, patient-study initiation, financing support, and whether early trials can show that axon preservation produces functional benefit.

Chemotherapy-induced peripheral neuropathy is the clearest first development setting because the nerve-injury trigger is known, the treatment window is definable, and there is no FDA-approved therapy that directly prevents chemotherapy-related axon loss. ALS and multiple sclerosis offer larger strategic value, but they require stronger evidence because disease biology is more complex and functional outcomes are harder to shift.

 

Why the SARM1 Inhibitors are Commercially Relevant

SARM1 inhibition is commercially relevant because axon degeneration is a shared downstream mechanism across multiple neurological diseases. In CIPN, neurotoxic chemotherapy damages peripheral nerves. In ALS, motor neuron and axonal loss drive progressive disability. In MS, inflammatory injury is increasingly linked to long-term neuroaxonal damage. In diabetic neuropathy, chronic metabolic stress damages peripheral nerves over time.

Current treatment options rarely address axon loss directly. CIPN care is mostly based on chemotherapy dose adjustment, symptom control, and pain management. ALS therapies offer limited slowing of functional decline. MS therapies reduce inflammatory disease activity but do not fully prevent neuroaxonal injury. Diabetic neuropathy care focuses mainly on glucose control, pain relief, and complication prevention.

This creates the core white space for SARM1 inhibitors: moving neurological care from symptom management toward axon preservation. The market will only mature if this mechanism produces clinically visible benefit, not merely target engagement.

 

Disease Burden and Trial-Relevant Patient Pools

The first commercially relevant pool is chemotherapy-induced peripheral neuropathy. The United States is expected to record about 2.11 million new cancer cases in 2026, while global cancer incidence was close to 20 million new cases in 2022. Only a subset receives neurotoxic chemotherapy, but that subset is clinically meaningful because taxanes, platinum drugs, vinca alkaloids, and proteasome inhibitors are widely used across major cancers.

CIPN has a practical development advantage because timing can be linked to chemotherapy exposure. Systematic evidence has reported CIPN prevalence of about 68% one month after chemotherapy, around 60% at three months, and about 30% at six months or later. This creates a clear clinical rationale for prevention or early intervention, especially where neuropathy disrupts cancer treatment continuity or survivorship quality of life.

Peripheral neuropathy beyond cancer provides a larger long-term opportunity. General peripheral neuropathy prevalence is estimated at about 2.4% of the population and rises to around 8% in older adults. Diabetes is a major driver of neuropathy risk, with the International Diabetes Federation reporting 589 million adults living with diabetes worldwide. However, diabetic neuropathy would likely require longer studies and stronger functional endpoints than CIPN.

ALS is smaller but strategically important. The CDC projects about 34,720 adults living with ALS in the United States in 2026, with roughly 5,000 new diagnoses annually. Its commercial relevance comes from severity, rapid progression, and high unmet need rather than population size.

Multiple sclerosis adds another important neuroaxonal-injury pool. Nearly 1 million people in the United States have MS, while the Atlas of MS estimates about 2.9 million people worldwide. SARM1 inhibition would not replace immune-modifying MS therapies, but it could become relevant if trials show protection against neurodegenerative progression or disability accumulation.

 

Current Treatment Gap

The strongest unmet need is in diseases where nerve injury becomes structural axon loss. CIPN has no approved preventive neuroprotective therapy. Duloxetine may help painful CIPN in selected patients, but it does not directly preserve axons during chemotherapy exposure.

ALS and MS already have disease-modifying treatment landscapes, but disability progression remains a major limitation. In ALS, functional decline continues despite available therapies. In MS, relapses can be controlled more effectively than progressive neuroaxonal injury. In diabetic neuropathy, treatment remains heavily oriented toward symptom relief, metabolic control, and complication prevention.

This gap supports SARM1 development, but it also raises the evidence bar. The class must show more than biological plausibility. It must show that preserving axons changes outcomes that matter clinically.

 

Pipeline Landscape and Development Signals

The SARM1 pipeline remains early, but it has moved beyond academic biology into clinical development. Sironax is one of the most visible developers through SIR2501, an oral allosteric SARM1 inhibitor. The asset completed Phase I evaluation, and the FDA granted Fast Track designation for chemotherapy-induced peripheral neuropathy in 2026. This is the strongest near-term category signal because it links SARM1 inhibition to a defined indication with high unmet need and no approved preventive therapy.

Nura Bio is advancing NB-4746, an oral brain-penetrant SARM1 inhibitor designed for central, peripheral, and ocular nervous system diseases. The company initiated Phase I testing in healthy volunteers and secured financing to support proof-of-biology development. Its differentiation lies in CNS penetration and broader applicability beyond peripheral neuropathy.

Eli Lilly entered the field through its acquisition of Disarm Therapeutics in 2020. Disarm’s platform was built around SARM1 inhibition for axonal degeneration in peripheral neuropathy and neurological diseases such as ALS and MS. Lilly’s public asset-level disclosure remains limited, but the acquisition validated SARM1 as a large-pharma neuroscience target.

Asha Therapeutics is developing ASHA-624, described as an intra-molecular glue inhibitor of SARM1, with support from the ALS Association’s Barnett Drug Development Program. Its relevance is different from CIPN-focused programs because it connects SARM1 inhibition directly to ALS-focused translational development.

Other research and discovery-stage activity from companies and research groups including Roche, AstraZeneca, Denali-linked programs, Tenvie Therapeutics, and additional neuroscience developers shows that the field is broadening. Most of these programs remain preclinical or undisclosed, so they should be treated as optionality rather than near-term commercial competition.

 

Clinical Proof Requirements

The central question for SARM1 inhibitors is whether axon preservation can be measured early enough and linked to patient benefit. In CIPN, the most relevant endpoints include neuropathy severity scores, patient-reported numbness or tingling, pain outcomes, sensory testing, nerve conduction measures, chemotherapy dose continuity, and persistence of neuropathy after chemotherapy completion.

CIPN offers the cleanest first proof-of-concept path because the injury trigger is known and treatment timing can be matched to chemotherapy exposure. A positive signal in this setting would validate the mechanism in a real-world nerve-injury model and support broader neuropathy development.

ALS and MS will require different proof standards. ALS studies may need to show slower functional decline, respiratory preservation, muscle-strength benefit, or biomarker movement such as neurofilament light chain reduction. MS studies may focus on disability progression, imaging, optic nerve injury, neurofilament light chain, and long-term neuroaxonal preservation.

Across all indications, biomarkers will matter because functional outcomes may take time. Neurofilament light chain, nerve conduction, quantitative sensory testing, imaging-based axonal markers, and disease-specific functional scales may help connect early biological activity to clinical relevance.

 

Development Strategy and Differentiation

SARM1 inhibitor differentiation will depend on tissue reach, depth of NADase inhibition, dosing convenience, chronic safety, and indication fit. Peripheral neuropathy programs must show compatibility with chemotherapy or metabolic disease care. CNS programs require brain penetration, longer exposure, and evidence that drug activity reaches disease-relevant neurons.

SIR2501 currently has the clearest near-term development position because of its Phase I completion and Fast Track designation in CIPN. NB-4746 is differentiated by its brain-penetrant design and broader CNS/PNS ambition. Lilly’s Disarm-derived platform remains strategically important because it signals large-pharma interest, while Asha’s ASHA-624 adds ALS-focused optionality.

The most logical development sequence is CIPN first, followed by broader neuropathy and neurodegeneration expansion if human proof-of-biology is established. CIPN can validate the mechanism faster; ALS, MS, diabetic neuropathy, traumatic injury, and ocular neurodegeneration can expand the market later if endpoint and safety hurdles are cleared.

 

Clinical Translation Risks

The main risk is that SARM1 inhibition may preserve axons biologically without producing enough functional improvement in complex human disease. ALS, MS, diabetes, and traumatic nerve injury involve overlapping mechanisms such as inflammation, mitochondrial stress, immune injury, metabolic dysfunction, and cell-body degeneration.

Timing will be critical. SARM1 activation occurs during the axonal injury cascade, so treatment may need to begin before damage becomes irreversible. That is feasible in CIPN, where chemotherapy creates a predictable risk window, but more difficult in chronic neurodegenerative diseases where diagnosis often occurs after substantial injury.

Endpoint selection could also determine success. Pain reduction alone may not prove axon protection, while biomarker movement alone may not satisfy clinicians or payers. Future trials must connect SARM1 inhibition to less neuropathy, preserved mobility, slower disability progression, better nerve function, or reduced chemotherapy disruption.

Safety is another important hurdle. Cancer patients receiving chemotherapy, ALS patients with progressive weakness, MS patients using immunomodulatory therapies, and diabetic neuropathy patients with cardiometabolic comorbidities may not tolerate added treatment burden. A successful SARM1 inhibitor must show neuroprotection without disrupting existing disease management.

 

Future Access Considerations

Pricing and reimbursement are not current market drivers because SARM1 inhibitors remain investigational. Future access will depend on indication, duration of therapy, clinical benefit, and whether the drug prevents disability or mainly improves symptoms.

CIPN prevention may support access if treatment reduces neuropathy severity, preserves chemotherapy dose intensity, or lowers long-term supportive-care burden. ALS may support premium pricing if functional decline is slowed. MS and diabetic neuropathy may face higher reimbursement thresholds because they involve larger chronic-use populations and existing treatment frameworks.

The access case will be strongest if SARM1 inhibitors are positioned as neuroprotective therapies that preserve nerve structure and function, not as another symptomatic pain-management option.

 

Strategic Commercial Opportunity

The strongest near-term opportunity lies in CIPN because the unmet need is clear, the patient population is identifiable, and the intervention window is clinically defined. A successful CIPN program could validate SARM1 inhibition as an axon-preserving mechanism and create a bridge into broader neuropathy and neurodegeneration indications.

The longer-term opportunity is larger but less certain. Diabetic neuropathy, ALS, MS, traumatic nerve injury, and ocular neurodegeneration could expand the market if early trials show that SARM1 inhibition preserves nerve function across different axonopathy settings. Companies that can connect mechanism, biomarker movement, functional outcomes, and safety will be best positioned to lead the category.

 

Market Outlook

The SARM1 inhibitors market remains in a clinical validation phase, but the mechanism has one of the clearer biological rationales in neuroprotection. SARM1 activation links nerve injury to NAD+ depletion and programmed axon degeneration, making it a relevant target where axon loss drives long-term disability.

 

SARM1 Inhibitors Market Report Coverage Table

Report Attribute	Details
Forecast Period	2024 – 2030
Market Size Value in 2024	USD 120 Million
Revenue Forecast in 2030	USD 540 Million
Overall Growth Rate	CAGR of 28.5% (2024 – 2030)
Base Year for Estimation	2024
Historical Data	2019 – 2023
Unit	USD Million, CAGR (2024 – 2030)
Segmentation	By Application, By Molecule Type, By Distribution Channel, By Geography
By Application	ALS, Peripheral Neuropathies, TBI & Spinal Injuries, MS, Chemotherapy-Induced Neuropathy, Others
By Molecule Type	Small Molecule Inhibitors, Biologics & Peptides, Gene & RNA-based Approaches
By Distribution Channel	Hospital Pharmacies, Specialty Clinics, Online & Specialty Pharmacies
By Region	North America, Europe, Asia-Pacific, Latin America, Middle East & Africa
Country Scope	U.S., Germany, U.K., China, Japan, South Korea, Brazil, etc.
Market Drivers	- Rising prevalence of neurodegenerative diseases - Platform potential across multiple indications - Orphan and fast-track regulatory incentives
Customization Option	Available upon request